EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Neofect Co.Ltd (290660) fair value: what the stock is really worth

As of Oct 16, 2026: fair value (intrinsic value) of Neofect Co.Ltd stock KRW 305, price KRW 1,240, upside -75.4%, quality 20 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7290660000

NC Neofect Co.Ltd logo Thin data Oct 2, 2026

Neofect Co.Ltd

290660 · KQ

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 75% below what the stock costs today.

Low debt
Fair value 305.47 KRW · Strongly overvalued (−75.4%)
Quality 20/100
Weak Growth (revenue 5y −2.9 %/yr in KRW)
Loss-making · -37.2% net margin (TTM)
Negative free cash flow
Trails peers (1/8)
Narrow moat 12/100
Thin data
⚠ Dilution
Watch Neofect Co.Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

8,570 KRW 1,059 KRW Fair Value 305.47 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 1,059 KRW – 8,570 KRW · fair‑value band 201.61 KRW – 381.84 KRW · the 1,240 KRW price screens above the 305.47 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.

Follow Neofect Co.Ltd in your weekly email

Every Wednesday you see whether Neofect Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dynamic solution Co.,Ltd. researches, develops, manufactures, and sells rehabilitation medical devices and contents for stroke and spinal cord injuries.

Show moreShow less

The company offers Neofect Smart Glove, a high-tech rehab device that measures movements of the forearm, wrist, and digits with accelerometer and bending sensors; Neofect Smart Kids for hand rehabilitation in children; Neofect Smart Board, a high-tech medical device that develops users' shoulder and upper arm movements to promote improved functional reach and muscle control; Neofect Smart Balance to practice balance and posture during real-world training scenarios; and Neofect Smart Pegboard, a digital pegboard for functional and cognitive rehabilitation.

It also provides Neofect Smart Table for dementia prevention and rehabilitation program; Neomano, a wearable robotic glove; Neofect Comcog, a cognitive rehabilitation program that helps patients with stroke, dementia, traumatic brain injury, brain tumor, and cerebral palsy; and Neofect TeleRehab, a teletherapy platform designed for remote rehabilitation, as well as a range of orthotic and assistive devices.

The company was formerly known as Neofect Co., Ltd. and changed its name to Dynamic solution Co.,Ltd. in April 2026. The company was incorporated in 2010 and is headquartered in Seongnam-si, South Korea.

Stock analysis

Neofect Co.Ltd (290660) currently trades at 1,240 KRW, while our model-based Fair Value estimate is 305.47 KRW, 75.4% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: 201.61 KRW (bear) to 381.84 KRW (bull), the price of 1,240 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Neofect Co.Ltd reported revenue of 16.1B KRW in FY2025 versus 23.2B KRW in FY2021, a compound −8.8%/yr. Reported net income was −12.3B KRW in FY2025.

Key figures

Market cap 62.6B KRW (≈ $47.1M) · P/S ratio 3.65 · Net margin −76.6% · Return on equity −9.8% · Return on assets (EBIT) −8.2% · Operating margin −22.8% · Revenue (TTM) 15.1B KRW · Revenue growth (YoY) −7.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −75%, 290660 screens richer than that median.

Fair Value models

Bear 201.61 KRW Fair Value 305.47 KRW Bull 381.84 KRW
Price 1,240 KRW · Upside -75.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 622.49 KRW 834.14 KRW 1,245 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 622.49 KRW 834.14 KRW 1,245 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 20/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 13
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 19
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 14
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−24.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−78.7% (2020) → −18.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

290660 screens overvalued: fair value 75% below the price. Compare with Abbott Laboratories, →

Compare Neofect Co.Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside −75.4% · Bottom 25%
Profitability
Return on assets −15.8% · Bottom 25%
Net margin (12 months) −37.2% · Bottom 25%
Operating margin (12 months) −22.8% · Bottom 25%
Growth and dividend
Revenue growth −7.7% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 7
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 16
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $282.60 $310.86 +10% vs 290660
Boston Scientific Corporation BSX $43.00 $47.30 +10% vs 290660
DexCom, Inc DXCM $84.11 $92.52 +10% vs 290660
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥166.00 ¥182.60 +10% vs 290660
GE HealthCare Technologies Inc GEHC $65.74 $70.37 +7% vs 290660
Edwards Lifesciences Corporation EW $85.78 $81.94 −4% vs 290660
Siemens Healthineers AG SHL €38.26 €35.19 −8% vs 290660
Abbott Laboratories, ABT $102.61 $74.79 −27% vs 290660
Medtronic plc MDT $91.93 $65.61 −29% vs 290660
Koninklijke Philips N.V PHIA €22.18 €15.23 −31% vs 290660

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, survivorship-adjusted Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Neofect Co.Ltd · Fair Value
305.47 KRW −75%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Neofect Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/290660

Frequently asked questions

Is Neofect Co.Ltd (290660) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 305.47 KRW versus a price of 1,240 KRW, about −75% upside (overvalued).
What is the fair value of 290660?
Our model-based fair value for Neofect Co.Ltd is 305.47 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 1,240 KRW.
What is the quality score of 290660?
Neofect Co.Ltd has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neofect Co.Ltd (290660)?
Our model-based price target is the fair value of 305.47 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 201.61 KRW, optimistic scenario 381.84 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Neofect Co.Ltd stock forecast for 2026?
Our models put fair value at 305.47 KRW, about −75% upside versus a price of 1,240 KRW (overvalued). Cautious scenario 201.61 KRW, optimistic scenario 381.84 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Neofect Co.Ltd (290660)?
Neofect Co.Ltd reported trailing-twelve-month revenue of about 15.1B KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of Neofect Co.Ltd (290660)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neofect Co.Ltd it is 305.47 KRW per share (as of Oct 2, 2026), against a price of 1,240 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Neofect Co.Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 290660 trades above its calculated fair value: price 1,240 KRW, fair value 305.47 KRW, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 290660?
No. The price is what the market pays today (1,240 KRW); the fair value is what the company's own numbers justify (305.47 KRW). For Neofect Co.Ltd the two are 934.53 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Neofect Co.Ltd worth?
The market values Neofect Co.Ltd at about 62.6B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 1,240 KRW; our models calculate a fair value of 305.47 KRW per share.
What do the bullish and bearish scenarios say about 290660?
Our models span a range for Neofect Co.Ltd: cautious scenario 201.61 KRW, base 305.47 KRW, optimistic 381.84 KRW per share (as of Oct 2, 2026, price 1,240 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neofect Co.Ltd (290660)?
Balance-sheet figures for Neofect Co.Ltd (as of Oct 2, 2026): return on equity −9.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is 290660 from its 52-week high?
Neofect Co.Ltd trades at 1,240 KRW, about 62% below its 52-week high of 3,304 KRW and 17% above the low of 1,059 KRW (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of 305.47 KRW is for.
Which stocks are comparable to Neofect Co.Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neofect Co.Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price 1,240 KRW, calculated fair value 305.47 KRW (−75%), Quality Score 20/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 290660 calculated?
We run Neofect Co.Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 305.47 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.4 % above its aggregate fair value. Neofect Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neofect Co.Ltd (290660)?
The closing price on Oct 16, 2026 was 1,240 KRW. Our model-based fair value is 305.47 KRW, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neofect Co.Ltd right now?
The price sits above even our optimistic bull case (381.84 KRW). The favourable scenario is already priced in. Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (201.61 KRW to 381.84 KRW) leaves room in how you read the outcome.

Key figures of Neofect Co.Ltd

How large is the market capitalisation of Neofect Co.Ltd (290660)?
The market capitalisation of Neofect Co.Ltd is 62.6B KRW (≈ $47.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neofect Co.Ltd (290660)?
The price-to-sales ratio of Neofect Co.Ltd is 3.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Neofect Co.Ltd (290660)?
The net margin of Neofect Co.Ltd is −76.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neofect Co.Ltd (290660)?
The return on equity (ROE) of Neofect Co.Ltd is −9.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neofect Co.Ltd (290660)?
On an EBIT basis the return on assets of Neofect Co.Ltd is −8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neofect Co.Ltd (290660)?
The operating margin of Neofect Co.Ltd is −22.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neofect Co.Ltd (290660)?
Revenue at Neofect Co.Ltd is growing −7.7% versus a year earlier (3y avg −15.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Neofect Co.Ltd (290660)?
Earnings per share at Neofect Co.Ltd are growing +877% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Neofect Co.Ltd (290660) generate?
The free cash flow of Neofect Co.Ltd is −2.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Neofect Co.Ltd (290660) carry?
The net debt of Neofect Co.Ltd is 3.2B KRW (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Neofect Co.Ltd in the live analysis

One click puts Neofect Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.